Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Eye (Lond) ; 32(1): 55-66, 2018 01.
Artículo en Inglés | MEDLINE | ID: mdl-29265111

RESUMEN

PurposeTo correlate function and structural optical coherence tomography (OCT) to optical coherence tomography angiography (OCT-A) measures in patients affected by central serous chorioretinopathy (CSC) and to describe their changes after treatments (ie oral eplerenone, half-fluence photodynamic therapy (PDT)).Patients and methodsTwenty eyes of 16 consecutive patients with treatment-naïve CSC undergoing either eplerenone or PDT were enrolled in this prospective, observational study. All patients underwent structural OCT and OCT-A at baseline and after therapy at months 1 and 3.ResultsEleven eyes of nine patients and nine eyes of seven patients underwent eplerenone or PDT treatment, respectively. Central macular thickness (CMT) and subretinal fluid (SRF) correlated to fovea avascular zone (FAZ) area (r=0.74 and r=0.71, P=0.01) and vessel density (r=0.77 and r=0.68, P=0.01) at deep capillary plexus (DCP). CMT (P=0.0011), SRF (P=0.0005), SFCT (P=0.0016), FAZ area at DCP (P=0.0334) improved at 3-month visit. A significant reduction of deep FAZ area was appreciated in eplerenone (P=0.0204) but not in PDT (P=0.5) group. SFCT reduction was significantly higher in PDT than eplerenone group (P=0.0347).ConclusionStructural and vascular parameters are correlated in CSC and they improve after different treatments. Both half-fluence PDT and oral eplerenone do not permanently damage choriocapillaris or other choroidal layers as evaluated by OCT-A.


Asunto(s)
Coriorretinopatía Serosa Central/tratamiento farmacológico , Angiografía con Fluoresceína/métodos , Imagen Multimodal , Fotoquimioterapia/métodos , Fármacos Fotosensibilizantes/uso terapéutico , Espironolactona/análogos & derivados , Tomografía de Coherencia Óptica/métodos , Administración Oral , Adulto , Coriorretinopatía Serosa Central/diagnóstico , Coroides/patología , Eplerenona , Femenino , Estudios de Seguimiento , Fondo de Ojo , Humanos , Masculino , Persona de Mediana Edad , Antagonistas de Receptores de Mineralocorticoides/administración & dosificación , Estudios Prospectivos , Retina/patología , Espironolactona/administración & dosificación , Agudeza Visual
SELECCIÓN DE REFERENCIAS
Detalles de la búsqueda